Navigation Links
Reducing the side effects of treatment for prostate cancer
Date:8/27/2012

New research published in BioMed Central's open access journal BMC Medicine reassessing clinical data from trials, which investigate ways of treating side effects of therapy for prostate cancer, finds that tamoxifen, an anti-estrogen used to treat breast cancer, is also able to suppress gynecomastia and breast pain in men.

Prostate cancer is one of the most common cancers in men and early treatment is usually very successful. Androgen-suppression therapy is often used to slow down progression of advanced disease. However, unwanted side effects of anti-androgen treatment, such as breast enlargement, can stop men from seeking treatment for their cancer.

Testosterone can drive the growth of prostate cancer and anti-androgens are used to inhibit prostate cancer growth by preventing testosterone from binding to androgen receptors. But receptors in cells within the testes are also blocked and start to make more testosterone to compensate. Some of this extra testosterone is converted into estrogen which is responsible for development of breast tissue and other breast events. Anti-estrogens work by jamming the estrogen receptor, while aromatase inhibitors prevent the conversion of testosterone into estrogen.

A collaboration between the German Cochrane Center and University Clinic Erlangen combined data from four independent clinical trials each looking at the management of breast events (during treatment for prostate cancer) with tamoxifen.

A meta-analysis of all four trials showed that tamoxifen reduced the risk of both gynecomastia and breast pain at 3, 6, 9, and 12 months of treatment compared to men who received no treatment. Overall, treatment with tamoxifen was more successful in reducing breast symptoms than treatment with an aromatase inhibitor (anastrazole) or radiotherapy.

Although there is no long term data available, few of the men treated with tamoxifen, either as preventative or therapeutic treatmen
'/>"/>

Contact: Hilary Glover
hilary.glover@biomedcentral.com
44-020-319-22370
BioMed Central
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Researchers determine vitamin D blood level for reducing major medical risks in older adults
2. Reducing post-traumatic stress after ICU
3. Reducing off-label use of antipsychotic medications may save money
4. No Progress in Reducing U.S. Motorcycle Deaths: Report
5. Kitchen exhaust fans vary in effectiveness in reducing indoor air pollution
6. HPV Vaccine Reducing Infections, Even Among Unvaccinated: Study
7. A nursing program shows promise for reducing deaths from chronic illnesses
8. Reducing Ozone Limits Would Save Lives, Report States
9. Timing of antibiotics important in reducing infections after C-section
10. Young girls more likely to report side effects after HPV vaccine
11. Preteens More Likely to Report HPV Vaccine Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... new UCLA study has shown this is definitely the case ... how to treat their prostate cancer. , UCLA researchers found ... a much more difficult time making treatment decisions, called decisional ... their care and their long-term outcomes. , The study should ... the findings to target men less likely to know a ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... 10 portions a week of tomatoes have an 18 ... research suggests. , With 35,000 new cases every year ... is the second most common cancer in men worldwide. ... experts believe is linked to a Westernised diet and ... recommendations reduces risk of prostate cancer, researchers at the ...
(Date:8/27/2014)... This news release is available in German . ... need for medical agents to treat metastatic tumors. In case ... cancer that is often detected late, 95% of the patients ... amcure develops tumor therapeutic agents that might reduce this mortality ... has now received a total of EUR 5 million from ...
(Date:8/27/2014)... CA (PRWEB) August 27, 2014 Bedros Keuilian ... franchise in the world, the leading fitness boot camp ... TV’s Gym Rescue reality series. One thing he knows very ... as a subject matter expert in the fitness business. , ... YouTube, he lays out a step-by-step instructional guide on how ...
Breaking Medicine News(10 mins):Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
... EP MedSystems,(Nasdaq: EPMD ) announces the following Webcast: What: ... 4:30 pm EST, Where: http://www.videonewswire.com/event.asp?id=43653 , How: ... web at the ... 856-753-8533, If ...
... in related literature. One extremely rare case was recently ... Journal of Gastroenterology because of its maximum diameter of ... clinical and histopathological findings, diagnostic methods and treatment by ... , The article reported one patient who presented to ...
... OCTOBER 25, 2007 Shire plc (LSE: ... biopharmaceutical company, announced that data from a 12-month ... Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA ... in children aged 6 to 12 years. ...
... formation of a cancer is proven to be a ... a definite carcinogen, the role of Helicobacter pylori (H ... unclear. An article to be published on November 7 ... mechanism explaining the promotional effect of H pylori on ...
... Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition") (NASDAQ: ... of US$7.5,million representing the second half of the ... agreement with a subsidiary of,Elan Corporation, plc ("Elan") ... drug,candidate ELND-005/AZD-103. ELND-005/AZD-103 has completed Phase I ...
... 500 health ... plans on quality of care, service, WASHINGTON, Oct. 26 ... Assurance (NCQA) today unveiled the third,edition of America,s Best Health ... plans. Coinciding with the,November launch of "open season," when many ...
Cached Medicine News:Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The largest colonic lipoma to date 2Health News:Long-term 12-month safety data on ADHD patch DAYTRANA 2Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3
(Date:8/26/2014)... Aug. 26, 2014  Actavis plc (NYSE: ACT ... Brenton Saunders , CEO and President of Actavis, will ... the Morgan Stanley Global Healthcare Conference 2014 in ... The presentation will take place on ... the Grand Hyatt New York, 109 East 42 nd ...
(Date:8/26/2014)... , Aug. 26, 2014 Reportlinker.com ... is available in its catalogue: ... 2020 http://www.reportlinker.com/p02280977/Japan-Esophagoscopes--Gastroscopes-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s ... Outlook to 2020", provides key market data ...
(Date:8/26/2014)... Research and Markets  has announced the ... 2014-2018" report to their offering. Intranasal ... the administration of drugs for the treatment of local ... allergic and non-allergic rhinitis and sinusitis. The nose is ... vaccination and systematic drug delivery. Continuous ...
Breaking Medicine Technology:Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... 2011 , The deadly E. ... thousands across Europe has been sequenced using 454,Life Sciences, ... and detailed genetic analysis to date" of this,particularly virulent ... performed by scientists at the UK,s Health,Protection Agency and ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Number of PE/VC Investments in Small ... in the Past Four Years ...
Cached Medicine Technology:Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 2Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 2Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 4Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 5Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 6Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 7Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 8Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 9Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 10Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 11
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... The Laserex Tango ophthalmic laser system ... an SLT laser and a photodisruptor for ... is a frequency-doubled Nd:YAG producing pulsed 532 ... Nd:YAG producing 1064 nm. The appropriate laser ...
... is the unique combination laser system for ... of a button switch between SLT or ... Selecta Duet affords you the opportunity to ... the same setting with the benefits inherent ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Medicine Products: